FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound having the general formula (I)
where R1, ring A and ring B are as described in the claims, which is used to inhibit the activity of RIP1 kinase, to a pharmaceutical composition containing this compound, to the use of this compound and to a method of treatment using this compound.
EFFECT: development of a new RIP1 kinase inhibitor useful for the treatment of diseases and disorders associated with inflammation, cell death and other causes.
28 cl, 2 tbl, 163 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BICYCLIC LACTAMS AND METHODS OF USE THEREOF | 2016 |
|
RU2827714C1 |
| Axl INHIBITORS APPLICABLE IN COMBINATION THERAPY FOR PREVENTING, RELIEVING OR TREATING METASTATIC CANCER | 2010 |
|
RU2555326C2 |
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
| PHTHALAZINE KETONE DERIVATIVE, METHOD OF OBTAINING THEREOF AND PHARMACEUTICAL APPLICATION | 2011 |
|
RU2564527C2 |
| DERIVATIVES OF 7-PHENOXY-N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-b][1,2,4]TRIAZOLE-2-AMINE AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR TREATING ALZHEIMER'S DISEASE | 2019 |
|
RU2841048C2 |
| PYRIDAZINE DERIVATIVES AS RORc MODULATORS | 2017 |
|
RU2757571C2 |
| AZALACTAM COMPOUNDS AS INHIBITORS OF HPK1 | 2021 |
|
RU2819642C1 |
| COMPOUND HAVING INHIBITORY ACTIVITY ON KDM5, AND PHARMACEUTICAL USE THEREOF | 2021 |
|
RU2840256C1 |
| AZADECALINS CONDENSED WITH HETEROARYLKETONES - GLUCOCORTICOID RECEPTOR MODULATORS | 2013 |
|
RU2639867C2 |
| SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-7-YL COMPOUNDS AS THE INHIBITORS OF PDE2 | 2015 |
|
RU2659070C9 |
